04/09/2026
Following yesterday’s announcement, here’s a little more about why we invested in Bioactivx®:
Collagen has long been a go-to material for treating serious burns and deep wounds. But a treatment can work well and still be out of reach, whether it’s unsuitable for certain patients for religious reasons or for patients in remote areas that are distant from burn centres, which are usually situated in major cities.
That’s the gap our portfolio company, Bioactivx®, has set out to close with its Bioactiv® Matrix.
BioactivX® Matrix is a fully synthetic wound-care matrix designed to outperform collagen without the constraints of animal-derived materials. No animal tissue. It can be used outside a sterile operating theatre, helping reduce the risk of infection. A two-year shelf life makes advanced wound care more practical to transport, store, and deploy where it is needed most.
In simple terms: Bioactiv® Matrix takes the benefits of advanced wound care and removes many of the barriers that make it difficult to deliver.
We’re proud to share that Bioactivx® has closed a US$3M Pre-Series A, co-led with Martin Krupp, to scale manufacturing here in Singapore and bring Bioactiv® Matrix to more patients and more places.
Congratulations to co-founders Peili Teo, Yew Lok Woo, and the entire Bioactivx team, and to Agency for Science, Technology and Research (A*STAR) and SingHealth for backing this journey from the beginning. 🧬
Find out how Michael Blakey decided to invest, and why the way Peili explained the problem mattered as much as the product itself: https://www.linkedin.com/posts/mblakey_vcthursdayswithmichael-cocoonportco-bioactivx-activity-7501089695725178880-BbAS?utm_source=share&utm_medium=member_desktop&rcm=ACoAABfIPZcBR4oxDCyDwd3x0-WekO10OrSRtLU